Genspera Inc (GNSZ) 1.2500 $GNSZ
IPOs and Transactions: March 17 - 21
PR Newswire - Mon Mar 24, 11:30AM CDT
There were 56 transactions filed with the SEC last week. Highlighted corporations and law firms include:
First Patient Enrolled in GenSpera G-202 Phase II Glioblastoma Trial
Business Wire - Tue Mar 18, 7:02AM CDT
GenSpera, Inc. (OTCQB:GNSZ) announced that the first patient was enrolled in the Phase II clinical trial of its lead compound, G-202, in patients who have glioblastoma multiforme (GBM), the most prevalent type of primary brain cancer. The trial is being conducted at UC San Diego Moores Cancer Center. This Phase II G-202 trial will treat up to 34 patients with GBM that has progressed or recurred after at least one other treatment.
GenSpera CEO, Craig Dionne, to Present at BIO CEO & Investor Conference, February 10th
Business Wire - Thu Feb 06, 8:02AM CST
GenSpera, Inc. (OTCQB:GNSZ) announced that Chairman and CEO, Craig Dionne, PhD, will deliver a company overview at the BIO CEO & Investor Conference 2014, on Monday, February 10th, at 1:30 PM. The conference is taking place at the Waldorf Astoria Hotel in New York, NY.
Research Reports: Kidney Cancer - Pipeline Review, H2 2013
M2 - Wed Nov 27, 2:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/jnwbgg/kidney_cancer) has announced the addition of the "Kidney Cancer - Pipeline Review, H2 2013" report to their offering. 'Kidney Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Kidney Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Kidney Cancer. Scope - A snapshot of the global therapeutic scenario for Kidney Cancer. - A review of the Kidney Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Kidney Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Kidney Cancer. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Kidney Cancer pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Amgen Inc. Amorfix Life Sciences Ltd. Astellas Pharma Inc. Onyx Pharmaceuticals, Inc. Patrys Limited Dendreon Corporation Green Cross Corporation Rexahn Pharmaceuticals, Inc. Antisense Pharma GmbH Chipscreen Biosciences Ltd CIMAB S.A. Aurigene Discovery Technologies Limited Alethia Biotherapeutics Inc. GenSpera, Inc. Cerulean Pharma, Inc. Gene Signal International SA. Neotropix, Inc. Deciphera Pharmaceuticals, LLC MSM Protein Technologies, Inc. Vascular Biogenics Ltd. Pharminox Limited Esperance Pharmaceuticals, Inc. Welichem Biotech Inc. Cellceutix Corporation TRACON Pharmaceuticals, Inc. Advanced Cancer Therapeutics RECEPTA Biopharma S.A. Mediolanum farmaceutici S.p.A. FCB-Pharmicell Co.,Ltd. For more information visit http://www.researchandmarkets.com/research/jn...ney_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
GenSpera CEO to Present at New York Society of Security Analysts' Life Sciences Conference
Business Wire - Mon Oct 28, 7:02AM CDT
GenSpera, Inc. (OTCQB:GNSZ) announced that CEO, Craig Dionne, PhD, will present at the New York Society of Security Analysts' Life Sciences Conference on Oct 30th, at 10:45 am, in New York, NY (http://www.nyssa.org/programs/conferencesseminars/ctl/viewdetail/mid/754/itemid/867/d/20131030.aspx). Dr. Dionne will give an overview of the company and its lead drug candidate, G-202. The company reported data from the G-202 Phase I trial in solid-tumor cancers last week.
Final Phase I Data on GenSpera's G-202 Presented at Symposium on Molecular Targets and Cancer Therapeutics
Business Wire - Tue Oct 22, 7:02AM CDT
GenSpera, Inc. (OTCBB:GNSZ) announced that Devalingam Mahalingam, MD, PhD, principal investigator of the G-202 Phase II trial in hepatocellular carcinoma, presented final data from the G-202 Phase I clinical trial yesterday at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Boston, MA (http://www.aacr.org/home/scientists/meetings--workshops/molecular-targets-and-cancer-therapeutics.aspx). In presenting a poster called, "A First-in-Human, Phase I Clinical Study of G-202, a Thapsigargin-Based Prostate-Specific Membrane Antigen (PSMA)-Activated Prodrug, in Patients with Advanced Solid Tumors," Dr. Mahalingam reported that 27% of the patients exhibited stable disease and two of the five patients with hepatocellular carcinoma had a prolonged stable disease of more than nine months (nine cycles of treatment). The trial treated a total of 44 patients, with solid-tumor cancers who had failed on earlier therapies, with increasing dose levels. A subset of 16 patients received the recommended Phase II dosing regimen, which appeared to be well-tolerated. Dr. Mahalingam is an oncologist at the Cancer Therapy & Research Center at The University of Texas Health Science Center at San Antonio.
GenSpera Announces $5 Million in Private Financing
Business Wire - Mon Aug 19, 7:09AM CDT
GenSpera, Inc. (OTCBB:GNSZ) announced today it has entered into subscription agreements with accredited investors and qualified institutional buyers totaling approximately $5 million, in which the purchasers are acquiring 3,333,373 units for $1.50 per unit. GenSpera expects this offering to close on Monday, August 19, 2013. T.R. Winston & Company, LLC acted as Placement Agent for the offering.
OTC Daily Alert Stock Watch - GenSpera (OTCBB:GNSZ)
WorldStockWire - Tue Aug 13, 6:30PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2013
M2 - Fri Aug 02, 9:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8c4tpq/metastatic) has announced the addition of the "Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2013" report to their offering. 'Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer. Scope - A snapshot of the global therapeutic scenario for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer. - A review of the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Development - Bristol-Myers Squibb Company - Johnson & Johnson - AstraZeneca PLC - Eli Lilly and Company - Genentech, Inc. - Bavarian Nordic A/S - Merck & Co., Inc. - Emergent BioSolutions Inc. - Takeda Pharmaceutical Company Limited - Millennium Pharmaceuticals, Inc. - Novartis AG - GTx, Inc. - Teva Pharmaceutical Industries Limited - Progenics Pharmaceuticals, Inc. - Exelixis, Inc. - Aduro BioTech - Merck KGaA - Active Biotech AB - Oncolytics Biotech Inc. - Oncothyreon Inc - Osta Biotechnologies Inc. - Medivation, Inc. - Synta Pharmaceuticals Corp. - Supratek Pharma Inc. - CellCentric Ltd. - CureVac GmbH - GenSpera, Inc. - BIND Biosciences, Inc. - NewLink Genetics Corporation - Bellicum Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/8c4tpq/metastatic
GenSpera Receives Patent on Targeted Prostate Cancer Drugs
Business Wire - Thu Jun 06, 7:02AM CDT
GenSpera, Inc. (OTC.BB: GNSZ) announced that the United States Patent and Trademark Office (USPTO) issued patent 8,450,280 "Activation of Peptide Prodrugs by HK2." The patent covers the composition of a series of prodrugs activated by HK2 to deliver a thapsigargin derivative selectively to prostate cancers. HK2 is an enzyme secreted by prostate cancer cells. A derivative of thapsigargin, 12ADT, is the active component of G-202, GenSpera's lead drug candidate in Phase II clinical trials for liver cancer after sorafenib (Nexavar(R)) therapy.
GenSpera Chief Executive Officer Craig Dionne to Present to BIO Business Forum(TM) on April 23, 2013 in Chicago
Business Wire - Wed Apr 10, 7:02AM CDT
GenSpera, Inc. (OTCBB:GNSZ) today announced that Chairman and CEO, Craig Dionne, PhD, will deliver a company overview at the BIO Business Forum(TM) on Tuesday, April 23, 2013, at 10:30 AM CDT. The forum is held from April 22-25 in conjunction with the 2013 BIO International Convention, the largest international event for the biotech industry, at McCormick Place in Chicago, Illinois.
GenSpera's G-202 Granted U.S. Orphan Drug Designation for Treatment of Hepatocellular Carcinoma
Business Wire - Thu Mar 14, 7:02AM CDT
GenSpera, Inc. (OTCBB:GNSZ) announced that the U.S. Food and Drug Administration's Office of Orphan Products Development has granted Orphan Drug Designation to its lead candidate, G-202, for the treatment of hepatocellular carcinoma (HCC), the most common form of primary liver cancer. G-202 is currently in a Phase II clinical trial for patients with hepatocellular carcinoma whose disease has worsened on standard therapy for this indication.
GenSpera Announces First Patient Treated in G-202 Phase II Hepatocellular Carcinoma Trial
Business Wire - Thu Feb 21, 7:02AM CST
GenSpera, Inc. (OTCBB:GNSZ) announced that the first patient has been treated in the Phase II clinical trial of its lead compound, G-202, in patients who have hepatocellular carcinoma (HCC).
IPOs and Transactions: March 17 - 21
PR Newswire - Mon Mar 24, 11:30AM CDT
There were 56 transactions filed with the SEC last week. Highlighted corporations and law firms include:
First Patient Enrolled in GenSpera G-202 Phase II Glioblastoma Trial
Business Wire - Tue Mar 18, 7:02AM CDT
GenSpera, Inc. (OTCQB:GNSZ) announced that the first patient was enrolled in the Phase II clinical trial of its lead compound, G-202, in patients who have glioblastoma multiforme (GBM), the most prevalent type of primary brain cancer. The trial is being conducted at UC San Diego Moores Cancer Center. This Phase II G-202 trial will treat up to 34 patients with GBM that has progressed or recurred after at least one other treatment.
GenSpera CEO, Craig Dionne, to Present at BIO CEO & Investor Conference, February 10th
Business Wire - Thu Feb 06, 8:02AM CST
GenSpera, Inc. (OTCQB:GNSZ) announced that Chairman and CEO, Craig Dionne, PhD, will deliver a company overview at the BIO CEO & Investor Conference 2014, on Monday, February 10th, at 1:30 PM. The conference is taking place at the Waldorf Astoria Hotel in New York, NY.
Research Reports: Kidney Cancer - Pipeline Review, H2 2013
M2 - Wed Nov 27, 2:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/jnwbgg/kidney_cancer) has announced the addition of the "Kidney Cancer - Pipeline Review, H2 2013" report to their offering. 'Kidney Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Kidney Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Kidney Cancer. Scope - A snapshot of the global therapeutic scenario for Kidney Cancer. - A review of the Kidney Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Kidney Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Kidney Cancer. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Kidney Cancer pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Amgen Inc. Amorfix Life Sciences Ltd. Astellas Pharma Inc. Onyx Pharmaceuticals, Inc. Patrys Limited Dendreon Corporation Green Cross Corporation Rexahn Pharmaceuticals, Inc. Antisense Pharma GmbH Chipscreen Biosciences Ltd CIMAB S.A. Aurigene Discovery Technologies Limited Alethia Biotherapeutics Inc. GenSpera, Inc. Cerulean Pharma, Inc. Gene Signal International SA. Neotropix, Inc. Deciphera Pharmaceuticals, LLC MSM Protein Technologies, Inc. Vascular Biogenics Ltd. Pharminox Limited Esperance Pharmaceuticals, Inc. Welichem Biotech Inc. Cellceutix Corporation TRACON Pharmaceuticals, Inc. Advanced Cancer Therapeutics RECEPTA Biopharma S.A. Mediolanum farmaceutici S.p.A. FCB-Pharmicell Co.,Ltd. For more information visit http://www.researchandmarkets.com/research/jn...ney_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
GenSpera CEO to Present at New York Society of Security Analysts' Life Sciences Conference
Business Wire - Mon Oct 28, 7:02AM CDT
GenSpera, Inc. (OTCQB:GNSZ) announced that CEO, Craig Dionne, PhD, will present at the New York Society of Security Analysts' Life Sciences Conference on Oct 30th, at 10:45 am, in New York, NY (http://www.nyssa.org/programs/conferencesseminars/ctl/viewdetail/mid/754/itemid/867/d/20131030.aspx). Dr. Dionne will give an overview of the company and its lead drug candidate, G-202. The company reported data from the G-202 Phase I trial in solid-tumor cancers last week.
Final Phase I Data on GenSpera's G-202 Presented at Symposium on Molecular Targets and Cancer Therapeutics
Business Wire - Tue Oct 22, 7:02AM CDT
GenSpera, Inc. (OTCBB:GNSZ) announced that Devalingam Mahalingam, MD, PhD, principal investigator of the G-202 Phase II trial in hepatocellular carcinoma, presented final data from the G-202 Phase I clinical trial yesterday at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Boston, MA (http://www.aacr.org/home/scientists/meetings--workshops/molecular-targets-and-cancer-therapeutics.aspx). In presenting a poster called, "A First-in-Human, Phase I Clinical Study of G-202, a Thapsigargin-Based Prostate-Specific Membrane Antigen (PSMA)-Activated Prodrug, in Patients with Advanced Solid Tumors," Dr. Mahalingam reported that 27% of the patients exhibited stable disease and two of the five patients with hepatocellular carcinoma had a prolonged stable disease of more than nine months (nine cycles of treatment). The trial treated a total of 44 patients, with solid-tumor cancers who had failed on earlier therapies, with increasing dose levels. A subset of 16 patients received the recommended Phase II dosing regimen, which appeared to be well-tolerated. Dr. Mahalingam is an oncologist at the Cancer Therapy & Research Center at The University of Texas Health Science Center at San Antonio.
GenSpera Announces $5 Million in Private Financing
Business Wire - Mon Aug 19, 7:09AM CDT
GenSpera, Inc. (OTCBB:GNSZ) announced today it has entered into subscription agreements with accredited investors and qualified institutional buyers totaling approximately $5 million, in which the purchasers are acquiring 3,333,373 units for $1.50 per unit. GenSpera expects this offering to close on Monday, August 19, 2013. T.R. Winston & Company, LLC acted as Placement Agent for the offering.
OTC Daily Alert Stock Watch - GenSpera (OTCBB:GNSZ)
WorldStockWire - Tue Aug 13, 6:30PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2013
M2 - Fri Aug 02, 9:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8c4tpq/metastatic) has announced the addition of the "Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2013" report to their offering. 'Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer. Scope - A snapshot of the global therapeutic scenario for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer. - A review of the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Development - Bristol-Myers Squibb Company - Johnson & Johnson - AstraZeneca PLC - Eli Lilly and Company - Genentech, Inc. - Bavarian Nordic A/S - Merck & Co., Inc. - Emergent BioSolutions Inc. - Takeda Pharmaceutical Company Limited - Millennium Pharmaceuticals, Inc. - Novartis AG - GTx, Inc. - Teva Pharmaceutical Industries Limited - Progenics Pharmaceuticals, Inc. - Exelixis, Inc. - Aduro BioTech - Merck KGaA - Active Biotech AB - Oncolytics Biotech Inc. - Oncothyreon Inc - Osta Biotechnologies Inc. - Medivation, Inc. - Synta Pharmaceuticals Corp. - Supratek Pharma Inc. - CellCentric Ltd. - CureVac GmbH - GenSpera, Inc. - BIND Biosciences, Inc. - NewLink Genetics Corporation - Bellicum Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/8c4tpq/metastatic
GenSpera Receives Patent on Targeted Prostate Cancer Drugs
Business Wire - Thu Jun 06, 7:02AM CDT
GenSpera, Inc. (OTC.BB: GNSZ) announced that the United States Patent and Trademark Office (USPTO) issued patent 8,450,280 "Activation of Peptide Prodrugs by HK2." The patent covers the composition of a series of prodrugs activated by HK2 to deliver a thapsigargin derivative selectively to prostate cancers. HK2 is an enzyme secreted by prostate cancer cells. A derivative of thapsigargin, 12ADT, is the active component of G-202, GenSpera's lead drug candidate in Phase II clinical trials for liver cancer after sorafenib (Nexavar(R)) therapy.
GenSpera Chief Executive Officer Craig Dionne to Present to BIO Business Forum(TM) on April 23, 2013 in Chicago
Business Wire - Wed Apr 10, 7:02AM CDT
GenSpera, Inc. (OTCBB:GNSZ) today announced that Chairman and CEO, Craig Dionne, PhD, will deliver a company overview at the BIO Business Forum(TM) on Tuesday, April 23, 2013, at 10:30 AM CDT. The forum is held from April 22-25 in conjunction with the 2013 BIO International Convention, the largest international event for the biotech industry, at McCormick Place in Chicago, Illinois.
GenSpera's G-202 Granted U.S. Orphan Drug Designation for Treatment of Hepatocellular Carcinoma
Business Wire - Thu Mar 14, 7:02AM CDT
GenSpera, Inc. (OTCBB:GNSZ) announced that the U.S. Food and Drug Administration's Office of Orphan Products Development has granted Orphan Drug Designation to its lead candidate, G-202, for the treatment of hepatocellular carcinoma (HCC), the most common form of primary liver cancer. G-202 is currently in a Phase II clinical trial for patients with hepatocellular carcinoma whose disease has worsened on standard therapy for this indication.
GenSpera Announces First Patient Treated in G-202 Phase II Hepatocellular Carcinoma Trial
Business Wire - Thu Feb 21, 7:02AM CST
GenSpera, Inc. (OTCBB:GNSZ) announced that the first patient has been treated in the Phase II clinical trial of its lead compound, G-202, in patients who have hepatocellular carcinoma (HCC).
